| Supplier |
Creative Peptides |
| Product # |
10-101-40 |
| CAS # |
3397-23-7 |
| Pricing |
Inquire
|
| Synonyms |
Ornithine Vasopressin; Ornithine-8-Vasopressin; Orpressin; POR-8; Ornipressina; Ornipressin; Ornipresina; POR8; POR 8
|
| MolecularFormula |
C45H63N13O12S2
|
| MolecularWeight |
1042.19
|
| Source |
Synthetic
|
| Sequence |
Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Orn-Gly-NH2(Cys1-Cys6)
|
| Storage |
Store at -20°C for up to 1 year.
|
| ShippingCondition |
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
|
| Explanation |
Ornipressin (omithine-8-vasopressin, POR-8) is the most commonly used vasopressin analogue in Germany, Switzerland, New Zealand and Australia. While it has minimal antidiuretic activity whilst maintaining equipotent vasoconstrictor activity as the natural hormone, vasoprssin.
|
| Application |
Ornipressin is a vasoconstrictor, haemostatic and renal agent.
|
| Solubility |
Soluble in DMSO, not in water
|
| Appearance |
Solid powder
|
| BiologicalActivity |
Ornipressin is a potent vasoconstrictor, hemostatic and renal agent.
|
| Reference |
- We sought to evaluate the efficacy and side effect profile of a small dose of ornipressin, a vasopressin agonist specific for the V1 receptor, administered to reverse the hypotension associated with combined general/epidural anesthesia. A total of 60 patients undergoing intestinal surgery were studied. After the induction of anesthesia, 7-8 mL of bupivacaine 0.5% with 2 microg/kg clonidine and 0.05 microg/kg sufentanil after an infusion of 5 mL of bupivacaine 0.06% with 0.5 microg x kg(-1) x h(-1) clonidine and 0.1 microg/h of sufentanil were administered by an epidural catheter placed at T7-8 vertebral interspace. When 20% reduction of baseline arterial blood pressure developed, patients were randomly assigned to receive, in a double-blinded design, dopamine started at 2 microg x kg(-1) x min(-1), norepinephrine started at 0.04 microg x kg(-1) x min(-1), or ornipressin started at 1 IU/h. Fifteen patients presenting without hypotension were used as control subjects. Beside routine monitoring, S-T segment analysis, arterial lactacidemia, and gastric tonometry were performed. Ornipressin restored arterial blood pressure after 8 +/- 2 vs 7 +/- 3 min in the norepinephrine group and 11 +/- 3 min in the dopamine group (P < 0.05). This effect was achieved with 2 IU/h of ornipressin in most of the patients (11 of 15). Ornipressin did not induce any modification of the S-T segment; however, it significantly increased intracellular gastric PCO(2) (P < 0.05), indicating splanchnic vasoconstriction.
- De Kock, M., Laterre, P. F., Andruetto, P., Vanderessen, L., Dekrom, S., Vanderick, B., & Lavand'homme, P. (2000). Ornipressin (Por 8): an efficient alternative to counteract hypotension during combined general/epidural anesthesia. Anesthesia & Analgesia, 90(6), 1301-1307.
|
| Purity |
>98% (or refer to the Certificate of Analysis)
|
| AreasOfInterest |
- Cardiovascular System & Diseases
- Pituitary & Hypothalamic Hormones
|
| ShortTermStorageConditions |
Dry, dark and at 0 - 4 °C
|
| LongTermStorageConditions |
-20 °C
|
| Functions |
Peptide binding
|
| Disease |
- Endometriosis
- Precocious puberty
|
| Organism |
Human
|
| LabelingTarget |
Gonadotropin-releasing hormone (GNRH) Receptor
|